Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial

in European Journal of Endocrinology
Authors:
Nicholas RussellDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Australia
Department of Endocrinology, Austin Health, Heidelberg, Australia

Search for other papers by Nicholas Russell in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-5596-6601
,
Rudolf HoermannDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Australia

Search for other papers by Rudolf Hoermann in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-1326-4270
,
Ada S CheungDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Australia
Department of Endocrinology, Austin Health, Heidelberg, Australia

Search for other papers by Ada S Cheung in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-5257-5525
,
Jeffrey D ZajacDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Australia
Department of Endocrinology, Austin Health, Heidelberg, Australia

Search for other papers by Jeffrey D Zajac in
Current site
Google Scholar
PubMed
Close
, and
Mathis GrossmannDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Australia
Department of Endocrinology, Austin Health, Heidelberg, Australia

Search for other papers by Mathis Grossmann in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-8261-3457
View More View Less

Correspondence should be addressed to N Russell; Email: nicholas.russell@austin.org.au
Restricted access

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

Objective

Most men undergoing androgen deprivation therapy (ADT) for prostate cancer experience hot flushes. Current treatments have low or limited evidence of efficacy. It is likely that oestradiol depletion is the mediator of these hot flushes, and transdermal oestradiol might be an effective treatment.

Design

This is a 6-month randomised, placebo-controlled trial with the hypothesis that oestradiol would reduce hot flush frequency and intensity and improve quality of life (QoL).

Methods

Seventy-eight participants receiving ADT were randomised to 0.9 mg of 0.1% oestradiol gel per day or matched placebo. Hot flush frequency and severity were assessed by 7-day diary at baseline, month 1, month 3, and month 6. QoL was assessed by validated questionnaire.

Results

Oestradiol reduced daily hot flush frequency, with a mean adjusted difference (MAD) of –1.6 hot flushes per day (95% CI: –2.7 to –0.5; P = 0.04). The effect on weekly hot flush score was non-significant, with a MAD –19.6 (95% CI: –35.5 to –3.8; P = 0.11). On per protocol analysis, E2 significantly reduced daily hot flush frequency, with a MAD of –2.2 hot flushes per day (95% CI: –3.2 to –1.1; P = 0.001), and weekly hot flush score, with a MAD of –27.0 (–44.7 to –9.3; P = 0.02). Oestradiol had no significant effect on QoL.

Conclusion

We confirmed our hypothesis of a clinical effect of assignment to oestradiol to reduce hot flush frequency in men with castrate testosterone due to ADT. Transdermal oestradiol could be considered for men with burdensome hot flushes in whom other treatments have failed as long as the risk of breast effects and fat gain are considered.

 

  • Collapse
  • Expand

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 2489 2489 31
Full Text Views 91 91 0
PDF Downloads 120 120 0
  • 1

    Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Medical Journal of Australia 2011 194 301306. (https://doi.org/10.5694/j.1326-5377.2011.tb02979.x)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2

    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, Santis MD, Fossati N, Gross T, Henry AM & Joniau S et al.EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. European Urology 2017 71 618629. (https://doi.org/10.1016/j.eururo.2016.08.003)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3

    Cornford P, Bellmunt J, Bolla M, Briers E, Santis MD, Gross T, Henry AM, Joniau S, Lam TB & Mason MD et al.EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. European Urology 2017 71 630642. (https://doi.org/10.1016/j.eururo.2016.08.002)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4

    Cheung AS, Rooy de C, Hoermann R, Joon DL, Zajac JD, Grossmann M. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clinical Endocrinology 2017 86 388394. (https://doi.org/10.1111/cen.13249)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. International Journal of Urology 2004 11 735741. (https://doi.org/10.1111/j.1442-2042.2004.00896.x)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. Journal of Urology 1994 152 11701173. (https://doi.org/10.1016/S0022-5347(1732530-2)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, Jim HSL. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia. Cancer 2018 124 499506. (https://doi.org/10.1002/cncr.31024)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, Ahmadzai N, Skidmore B, Morgan SC & Bordeleau L et al. Comparing interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses. Oncology Nursing Forum 2020 47 E86E106. (https://doi.org/10.1188/20.ONF.E86-E106)

    • Search Google Scholar
    • Export Citation
  • 9

    National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, 2019. (available at: https://www.nice.org.uk/guidance/ng131). Accessed on 11/04/2022.

    • Search Google Scholar
    • Export Citation
  • 10

    Kaplan M, Ginex PK, Michaud LB, Fernández-Ortega P, Leibelt J, Mahon S, Rapoport BL, Robinson V, Maloney C & Moriarty KA et al.ONS GuidelinesTM for cancer treatment-related hot flashes in women with breast cancer and men with prostate cancer. Oncology Nursing Forum 2020 47 374399. (https://doi.org/10.1188/20.ONF.374-399)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11

    Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet: Oncology 2010 11 147154. (https://doi.org/10.1016/S1470-2045(0970338-9)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12

    Jayasena CN, Comninos AN, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzi-Engbeaya C, Abbara A, Ratnasabapathy R, Mogford J & Ng N et al. Neurokinin B administration induces hot flushes in women. Scientific Reports 2015 5 8466. (https://doi.org/10.1038/srep08466)

    • Search Google Scholar
    • Export Citation
  • 13

    Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, Hoveyda HR, Fraser GL. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. Journal of Clinical Endocrinology and Metabolism 2019 104 58935905. (https://doi.org/10.1210/jc.2019-00677)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstetrics and Gynecology 2007 109 588596. (https://doi.org/10.1097/01.AOG.0000254160.62588.41)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Taylor AP, Lee H, Webb ML, Joffe H, Finkelstein JS. Effects of testosterone and estradiol deficiency on vasomotor symptoms in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2016 101 34793486. (https://doi.org/10.1210/jc.2016-1612)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Russell N, Hoermann R, Cheung AS, Ching M, Zajac JD, Handelsman DJ, Grossmann M. Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology 2018 178 565576. (https://doi.org/10.1530/EJE-17-1072)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Russell N, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Grossmann M. Effects of estradiol on fat in men undergoing androgen deprivation therapy: a randomized trial. European Journal of Endocrinology 2021 186 923. (https://doi.org/10.1530/EJE-21-0663)

    • Search Google Scholar
    • Export Citation
  • 18

    Russell N Biological actions of estradiol in men trial: registration on the Australian and New Zealand Clinical Trials Registry, 2014. (available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366524&showHistory=true&isReview=true). Accessed on 24/07/2022.

    • Search Google Scholar
    • Export Citation
  • 19

    Russell N, Hoermann R, Cheung A, Zajac J, Grossmann M. CONSORT Checklist: Effects of Estradiol Treatment on Hot Flushes and Quality of Life in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial. Figshare, 2022. (https://doi.org/10.6084/m9.figshare.19573849)

    • Search Google Scholar
    • Export Citation
  • 20

    NIH National Cancer Institute. Common terminology criteria for adverse events version 4.03, 2010. (available at: https://nciterms.nci.nih.gov/ncitbrowser/pages/advanced_search.jsf?dictionary=CTCAE&version=4.03). Accessed on 04/07/2017.

    • Search Google Scholar
    • Export Citation
  • 21

    Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE. Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine 1994 331 347352. (https://doi.org/10.1056/NEJM199408113310602)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22

    Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining ‘hot flashes’ in men. Urologic Nursing 1994 14 155158.

  • 23

    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993 11 570579. (https://doi.org/10.1200/JCO.1993.11.3.570)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24

    Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997 50 920928. (https://doi.org/10.1016/S0090-4295(9700459-7)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25

    Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The aging males’ symptoms rating scale: cultural and linguistic validation into English. Aging Male 2001 4 1422. (https://doi.org/10.1080/tam.4.1.14.22)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Moore C, Huebler D, Zimmermann T, Heinemann LAJ, Saad F, Thai DM. The aging males’ symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. European Urology 2004 46 8087. (https://doi.org/10.1016/j.eururo.2004.01.009)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27

    Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography–tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clinica Chimica Acta 2009 409 7884. (https://doi.org/10.1016/j.cca.2009.09.003)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28

    Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. Journal of Statistical Software 2015 67 148. (https://doi.org/10.18637/jss.v067.i01)

    • Search Google Scholar
    • Export Citation
  • 29

    R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2021.

  • 30

    Fox J, Weisberg S. Visualizing fit and lack of fit in complex regression models with predictor effect plots and partial residuals. Journal of Statistical Software 2018 87 127. (https://doi.org/10.18637/jss.v087.i09)

    • Search Google Scholar
    • Export Citation
  • 31

    Langley RE, Gilbert DC, Duong T, Clarke NW, Nankivell M, Rosen SD, Mangar S, Macnair A, Sundaram SK & Laniado ME et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised prostate adenocarcinoma transcutaneous hormone (PATCH) trial programme. Lancet 2021 397 581591. (https://doi.org/10.1016/S0140-6736(2100100-8)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32

    Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, Kanaga-Sundaram S, Dixit S, Laniado M & Madaan S et al. Quality-of-life outcomes from the prostate adenocarcinoma: transcutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU International 2017 119 667675. (https://doi.org/10.1111/bju.13687)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33

    Bennink HJTC, Moorselaar van JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, Haan de TD, Melick van HHE, Reisman Y & Zimmerman Y et al. Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi). European Urology Open Science 2021 28 5261. (https://doi.org/10.1016/j.euros.2021.04.005)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Miyajima M, Kusuhara H, Takahashi K, Takashima T, Hosoya T, Watanabe Y, Sugiyama Y. Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. Journal of Pharmaceutical Sciences 2013 102 33093319. (https://doi.org/10.1002/jps.23600)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35

    Handelsman DJ, Yeap BB, Flicker L, Martin S, Wittert GA, Ly LP. Age-specific population centiles for androgen status in men. European Journal of Endocrinology 2015 173 809817. (https://doi.org/10.1530/EJE-15-0380)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Russell N, Grossmann M. MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone. European Journal of Endocrinology 2019 181 R23R43. (https://doi.org/10.1530/EJE-18-1000)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37

    Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM, Atherton PJ, Marsa GW, Knutson WH & Bearden JD et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Annals of Oncology 2009 20 542549. (https://doi.org/10.1093/annonc/mdn644)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38

    Russell N, Cheung A, Grossmann M. Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocrine-Related Cancer 2017 24 R297R313. (https://doi.org/10.1530/ERC-17-0153)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Edmunds K, Tuffaha H, Galvão DA, Scuffham P, Newton RU. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Supportive Care in Cancer 2020 28 20792093. (https://doi.org/10.1007/s00520-019-05255-5)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40

    Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 2015 121 42864299. (https://doi.org/10.1002/cncr.29672)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41

    Nelson AM, Gonzalez BD, Jim HSL, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB. Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Supportive Care in Cancer 2016 24 41594166. (https://doi.org/10.1007/s00520-016-3241-z)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42

    Russell N, Allebone J, Dandash O, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Kanaan RA, Grossmann M. Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial. Clinical Endocrinology 2022 In press. (https://doi.org/10.1111/cen.14689)

    • Search Google Scholar
    • Export Citation